Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T13:41:48.888Z.
Calculation as of: 2026-10-06T13:41:48.888Z.
Quote observation: 2026-10-06T13:39:40.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c88c4f39e0f2b8ce509c05ad310ef4a925915372bb385716b1b31bbca6f45484
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$30.81M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$32.55M
Price/FCF Ratio
N/A
TTM Avg
507.99
3Y Avg
507.99
5Y Avg
507.99
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Context Therapeutics Inc. (CNTX) | $31.22M | N/A | N/A | N/A | N/A |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $30.81M | N/A | N/A | N/A | N/A |
| BeyondSpring Inc. (BYSI)vs › | $32.32M | N/A | N/A | N/A | N/A |
| EUDA Health Holdings Limited (EUDA)vs › | $32.55M | N/A | 507.99 | 507.99 | 507.99 |
| CervoMed Inc. (CRVO)vs › | $29.55M | N/A | N/A | N/A | N/A |
| HeartBeam, Inc. (BEAT)vs › | $33.20M | N/A | N/A | N/A | N/A |
| GridAI Technologies Corp. (GRDX)vs › | $29.02M | N/A | N/A | N/A | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $28.87M | N/A | N/A | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.18M | N/A | N/A | N/A | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.29M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
